Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini,Maximilian J Hochmair,Hannah Fabikan,Christoph Weinlinger,Amanda Tufman,Aurélie Swalduz,Kristina Lamberg,Sayed M.S. Hashemi,Florian Huemer,Anders Vikström,Martin Wermke,Gudrun Absenger,Alfredo Addeo,Shantanu Banerji,Antonio Calles,Stephen Clarke,Massimo Di Maio,Alice Durand,Michaël Duruisseaux,Malinda Itchins,Okko-Sakari Kääränien,Florian Krenn,Eckart Laack,Adrianus J. de Langen,Katja Mohorcic,Georg Pall,Antonio Passaro,Gerald W. Prager,Achim Rittmeyer,Jeffrey Rothenstein,Michael A. Schumacher,Ewald Wöll,Arschang Valipour

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

2021

Introduction:Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic ...

Keywords:

Targeted therapy
Cancer research
siren
RET Fusion Positive
Lung cancer
Medicine
retrospective analysis
Rearranged during transfection
non small cell
non-small cell lung cancer (NSCLC)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations